News from targovax A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages

Latest

03 Apr, 2020, 06:23 BST Targovax ASA Announces Proposed New Chairman of the Board

Targovax ASA (OSE: TRVX) announces that its nomination committee has nominated Mr. Damian Marron for election as Chairman of the Board at the...


11 Mar, 2020, 06:10 GMT Targovax ASA: Fourth Quarter 2019 Results

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


03 Mar, 2020, 06:17 GMT Targovax Announces Completed Enrollment in the ONCOS-102 Trial in Anti-PD1 Refractory Melanoma

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


21 Jan, 2020, 16:18 GMT Targovax Announces Encouraging Data in Mesothelioma Study Combining ONCOS-102 and Standard of Care Chemotherapy

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses to target hard-to-treat solid tumors, today announces ...


08 Jan, 2020, 12:07 GMT Updated Press Release: Targovax and IOVaxis Therapeutics Enters Option Agreement for TG Mutant RAS Vaccine License and Clinical Development in China

Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing oncolytic viruses and cancer vaccines to target hard-to-treat solid...


11 Nov, 2019, 06:28 GMT Presentation of ONCOS-102 Melanoma Data at SITC Annual Meeting

Targovax ASA (OSE: TRVX), announces that clinical data from its combination trial with ONCOS-102 and Keytruda in anti-PD1 refractory melanoma was...


07 Nov, 2019, 06:49 GMT Targovax ASA: Third Quarter 2019 Results

Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces...


09 Oct, 2019, 06:40 BST Targovax Selected for Oral Presentation at Society for Immunotherapy of Cancer (SITC) 2019 Annual Meeting

Targovax ASA (OSE: TRVX), announces that clinical data on the company's lead product candidate ONCOS-102, a genetically modified oncolytic adenovirus ...